Literature DB >> 31972762

Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting.

Margo E Godersky1, Jared W Klein, Joseph O Merrill, Kendra L Blalock, Andrew J Saxon, Jeffrey H Samet, Judith I Tsui.   

Abstract

INTRODUCTION/
BACKGROUND: Video directly observed therapy (video-DOT) through a mobile health platform may improve buprenorphine adherence and decrease diversion. This pilot study tested the acceptability and feasibility of using this technology among patients receiving buprenorphine in an office-based setting.
METHODS: Participants were instructed to record videos of themselves taking buprenorphine. Data were collected from weekly in-person visits over a 4-week period; assessments included self-report of medication adherence, substance use, satisfaction with treatment and use of the application, and also urine drug testing. Open-ended questions at the final visit solicited feedback on patients' experiences using the mobile health application.
RESULTS: The sample consisted of 14 patients; a majority were male (86%) and White (79%). All participants except 1 (93%) were able to use the application successfully to upload videos. Among those who successfully used the application, the percentage of daily videos uploaded per participant ranged from 18% to 96%; on average, daily videos were submitted by participants 72% of the time. Most participants (10/14; 71%) reported being "very satisfied" with the application; of the remaining 4 participants, 2 were "satisfied" and 2 were "neutral." Participants reported liking the accountability and structure of the application provided and its ease of use. Negative feedback included minor discomfort at viewing one's self during recording and the time required.
CONCLUSIONS: Based on these results, use of a mobile health application for video-DOT of buprenorphine appears feasible and acceptable for patients who are treated in an office-based setting. Further research is needed to test whether use of such an application can improve treatment delivery and health outcomes.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31972762      PMCID: PMC7358111          DOI: 10.1097/ADM.0000000000000608

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  32 in total

1.  Potential for abuse of buprenorphine in office-based treatment of opioid dependence.

Authors:  Theodore J Cicero; James A Inciardi
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

2.  Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Authors:  David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld
Journal:  N Engl J Med       Date:  2006-07-27       Impact factor: 91.245

3.  Buprenorphine in the United States: Motives for abuse, misuse, and diversion.

Authors:  Howard D Chilcoat; Halle R Amick; Molly R Sherwood; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2019-07-12

4.  Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.

Authors:  Jan Gryczynski; Jerome H Jaffe; Robert P Schwartz; Kristi A Dušek; Nishan Gugsa; Cristin L Monroe; Kevin E O'Grady; Yngvild K Olsen; Shannon Gwin Mitchell
Journal:  Am J Addict       Date:  2013 May-Jun

5.  Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.

Authors:  Alexander Y Walley; Julie K Alperen; Debbie M Cheng; Michael Botticelli; Carolyn Castro-Donlan; Jeffrey H Samet; Daniel P Alford
Journal:  J Gen Intern Med       Date:  2008-09       Impact factor: 5.128

6.  Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians.

Authors:  Chinazo O Cunningham; Hillary V Kunins; Robert J Roose; Rashiah T Elam; Nancy L Sohler
Journal:  J Gen Intern Med       Date:  2007-07-10       Impact factor: 5.128

7.  Factors affecting willingness to provide buprenorphine treatment.

Authors:  Julie Netherland; Michael Botsko; James E Egan; Andrew J Saxon; Chinazo O Cunningham; Ruth Finkelstein; Mark N Gourevitch; John A Renner; Nancy Sohler; Lynn E Sullivan; Linda Weiss; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2008-08-20

Review 8.  Mobile Delivery of Treatment for Alcohol Use Disorders: A Review of the Literature.

Authors:  Andrew Quanbeck; Ming-Yuan Chih; Andrew Isham; David Gustafson
Journal:  Alcohol Res       Date:  2014

9.  Monitoring Therapy Compliance of Tuberculosis Patients by using Video-Enabled Electronic Devices.

Authors:  Alistair Story; Richard S Garfein; Andrew Hayward; Valiantsin Rusovich; Andrei Dadu; Viorel Soltan; Alexandru Oprunenco; Kelly Collins; Rohit Sarin; Subhi Quraishi; Mukta Sharma; Giovanni Battista Migliori; Maithili Varadarajan; Dennis Falzon
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

10.  Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.

Authors:  Margo E Godersky; Andrew J Saxon; Joseph O Merrill; Jeffrey H Samet; Jane M Simoni; Judith I Tsui
Journal:  Addict Sci Clin Pract       Date:  2019-03-13
View more
  9 in total

1.  COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.

Authors:  Ximena A Levander; Jarratt D Pytell; Kenneth B Stoller; P Todd Korthuis; Geetanjali Chander
Journal:  Subst Abus       Date:  2021-10-19       Impact factor: 3.716

Review 2.  Digital directly observed therapy to monitor adherence to medications: a scoping review.

Authors:  Marie C D Stoner; Allysha C Maragh-Bass; Adam C Sukhija-Cohen; Parya Saberi
Journal:  HIV Res Clin Pract       Date:  2022-07-18

3.  Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.

Authors:  Judith I Tsui; Brian G Leroux; Andrea C Radick; Zachery A Schramm; Kendra Blalock; Colleen Labelle; Matthew Heerema; Jared W Klein; Joseph O Merrill; Andrew J Saxon; Jeffrey H Samet; Theresa W Kim
Journal:  Drug Alcohol Depend       Date:  2021-07-28       Impact factor: 4.852

4.  Rewarding recovery: the time is now for contingency management for opioid use disorder.

Authors:  Steven L Proctor
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

5.  Rapid Implementation of Service Delivery Changes to Mitigate COVID-19 and Maintain Access to Methadone Among Persons with and at High-Risk for HIV in an Opioid Treatment Program.

Authors:  K Michelle Peavy; James Darnton; Paul Grekin; Monica Russo; Caleb J Banta Green; Joseph O Merrill; Charissa Fotinos; Steve Woolworth; Sean Soth; Judith I Tsui
Journal:  AIDS Behav       Date:  2020-09

Review 6.  Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions.

Authors:  Mary M Sweeney; August F Holtyn; Maxine L Stitzer; David R Gastfriend
Journal:  Psychiatr Clin North Am       Date:  2022-07-31

Review 7.  Identification and Management of Opioid Use Disorder in Primary Care: an Update.

Authors:  Joseph H Donroe; Elenore P Bhatraju; Judith I Tsui; E Jennifer Edelman
Journal:  Curr Psychiatry Rep       Date:  2020-04-13       Impact factor: 5.285

8.  Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.

Authors:  Zachery A Schramm; Brian G Leroux; Andrea C Radick; Alicia S Ventura; Jared W Klein; Jeffrey H Samet; Andrew J Saxon; Theresa W Kim; Judith I Tsui
Journal:  Addict Sci Clin Pract       Date:  2020-07-31

Review 9.  Misalignment of Stakeholder Incentives in the Opioid Crisis.

Authors:  Alireza Boloori; Bengt B Arnetz; Frederi Viens; Taps Maiti; Judith E Arnetz
Journal:  Int J Environ Res Public Health       Date:  2020-10-16       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.